Innoviva (NASDAQ:INVA) Now Covered by Analysts at Oppenheimer

Stock analysts at Oppenheimer began coverage on shares of Innoviva (NASDAQ:INVA – Get Free Report) in a research report issued to clients and investors on Monday, Marketbeat Ratings reports. The brokerage set an “outperform” rating and a $45.00 price target on the biotechnology company’s stock. Oppenheimer’s price objective would indicate a potential upside of 123.99% […]

Leave a Reply

Your email address will not be published.

Previous post Jefferies Financial Group Has Lowered Expectations for MarketAxess (NASDAQ:MKTX) Stock Price
Next post Intellia Therapeutics (NASDAQ:NTLA) Price Target Cut to $60.00 by Analysts at Chardan Capital